Jaguar Health Inc. reported its first-quarter 2025 financial results, revealing a net revenue of approximately $2.2 million from its prescription and non-prescription products, including license revenue. This represents a 6% decrease from the net revenue of $2.4 million in the first quarter of 2024 and a significant 37% decline from $3.5 million in the fourth quarter of 2024. The company experienced an increase in Mytesi prescription volume by around 1.8% compared to the first quarter of 2024, but a decrease of 13.5% from the fourth quarter of 2024. The company reported a net loss attributable to common stockholders of $10.4 million for the first quarter of 2025, compared to a net loss of $9.2 million in the same period of the previous year. The loss from operations also increased by $1.2 million, reaching $9.4 million compared to $8.2 million in the first quarter of 2024. Notably, Jaguar Health highlighted proof-of-concept results showing that crofelemer reduced total parenteral nutrition in patients with rare orphan diseases, such as microvillus inclusion disease and short bowel syndrome with intestinal failure, by up to 27% and 12.5%, respectively. These results suggest potential to modify disease progression in intestinal failure patients. Additional proof-of-concept results are expected throughout 2025 for these conditions. Jaguar Health is also planning a meeting with the U.S. Food and Drug Administration (FDA) in the second quarter of 2025 regarding statistically significant results from the Phase 3 OnTarget trial of crofelemer in a prespecified subgroup of patients with breast cancer.